THMO - ThermoGenesis Holdings

  • Ecco la 60° Edizione del settimanale "Le opportunità di Borsa" dedicato ai consulenti finanziari ed esperti di borsa.

    Questa settimana abbiamo assistito a nuovi record assoluti in Europa e a Wall Street. Il tutto, dopo una ottava che ha visto il susseguirsi di riunioni di banche centrali. Lunedì la Bank of Japan (BoJ) ha alzato i tassi per la prima volta dal 2007, mettendo fine all’era del costo del denaro negativo e al controllo della curva dei rendimenti. Mercoledì la Federal Reserve (Fed) ha confermato i tassi nel range 5,25%-5,50%, mentre i “dots”, le proiezioni dei funzionari sul costo del denaro, indicano sempre tre tagli nel corso del 2024. Il Fomc ha anche discusso in merito ad un possibile rallentamento del ritmo di riduzione del portafoglio titoli. Ieri la Bank of England (BoE) ha lasciato i tassi di interesse invariati al 5,25%. Per continuare a leggere visita il link

BigNick

Siamo solo noi
Registrato
10/7/01
Messaggi
11.960
Punti reazioni
1.208
Anche questa come BKYI sembra essere molto sensibile,

si e' mossa parecchio (200%) in attesa e con gli Earnings ThermoGenesis Holdings Announces 2019 Year End Financial Results And Provides Corporate Update

ultimamente invece si e' mossa su notizie riguardanti il suo Rapid COVID-19 Serological Test Kit

ThermoGenesis Announces that it has Notified the FDA of its Intent to Distribute the Company'''s Rapid COVID-19 Point-of-Care Test Kit

ThermoGenesis''' Rapid COVID-19 Serological Test Kit Featured on FOX40 News Story Titled: "Rancho Cordova Company Develops Antibody Test to Detect COVID-19 in Minutes"

ThermoGenesis and ImmuneCyte'''s Rapid COVID-19 Testing Kit Featured on Local CBS News Titled: "Different Kind of Coronavirus Test"

inutile sottolineare la pericolosita' del titolo....

THMO.jpg
 
mi pare che sia l'ex CESCA , solo per precisare
 
Premarket

nel pre sta facendo +10%, in assenza di news ma, se non sbaglio anche giovedì scorso ha fatto la stessa cosa chiudendo poi con un modesto +3,45%,
vediamo oggi che fa :rolleyes:
 
in realtà ora una notizia è uscita: ThermoGenesis Announces Its ImmuneCyte Joint Venture Acquires Key Technologies to Develop Fully Human Polyclonal and Monoclonal Antibody Therapeutics for COVID-19

RANCHO CORDOVA, Calif., April 13, 2020 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, announced today that its joint venture, ImmuneCyte Life Sciences, Inc., has completed the acquisition of worldwide intellectual property for developing fully human antibody therapeutics for COVID-19. The acquired intellectual property includes four high-affinity monoclonal antibody drug candidates against SARS-CoV-2 (the virus causing COVID-19) and tools for screening and quantifying efficacy of such neutralizing antibodies. These high-affinity neutralizing monoclonal antibodies were obtained from the screening of enriched B cell libraries from individuals who have recently recovered from COVID-19 (i.e. from convalescent whole blood). The technologies were originally developed by a research team affiliated with East China Normal University, one of the most prestigious universities in China. The acquisition includes an undisclosed upfront cash payment and low double-digit future revenue sharing for the monoclonal antibody drug candidates under development. ThermoGenesis currently holds approximately 19% of the equity of ImmuneCyte.

There are currently no regulatory approved vaccine or drug therapies for COVID-19. Current estimates are that a vaccine for emergency use may be available by early 2021. Convalescent plasma therapy is an exploratory approach that involves giving patients an infusion of plasma from people who have recovered from COVID-19. ThermoGenesis is developing a convalescent plasma strategy for COVID-19 with its SARS-CoV-2 (COVID-19) IgM/IgG Antibody Fast Detection Kit, which, together with ImmuneCyte's newly acquired technologies, can quickly identify individuals who have developed protective immunity against the virus, and then, using ThermoGenesis' proprietary cell processing platform, allows for the simultaneous isolation of convalescent plasma and immune cells for potential anti-COVID-19 antibody development.

The key effectors in convalescent plasma are neutralizing antibodies, which can block the entrance of the virus into the cells, thus achieving its anti-viral effects. Purified neutralizing polyclonal and monoclonal antibodies could be safer and more potent and are expected to have much higher efficacy than convalescent plasma. With the acquisition of these key intellectual property technologies, ImmuneCyte will be further engaged in the development of anti- COVID-19 polyclonal and monoclonal neutralizing antibodies for COVID-19 treatment.

"The technologies acquired from a team associated with the world's leading institute in biological research will allow us to spearhead our antibody drug development against COVID-19," Chris Xu, Ph.D, Chairman and Chief Executive Officer of ThermoGenesis, commented, "Given the gravity of the situation, both ThermoGenesis and ImmuneCyte are rapidly mobilizing our respective expertise and resources to fight against the pandemic. The acquisition of the new technologies by ImmuneCyte, along with ThermoGenesis' established proprietary technologies in the automated cellular processing field, will allow us to develop highly efficient processing methods for making convalescent plasma and pursue the development of fully human polyclonal and monoclonal antibody therapies against COVID-19."
 
Non scherzava stamattina...

THMO.jpg

buoni anche i volumi
 
nervosetta stasera, chissà se domani esce qualche notizia, spero positiva....:rolleyes:
 
io vorrei anche venderle, ma prima di venderle mi piacerebbe sapere perchè stanno facendo +60% nel Pre :rolleyes:
 
Eccola la notizia che auspicavo ieri

ThermoGenesis Receives Acknowledgement Letter from FDA Allowing Its SARS-CoV-2 (COVID-19) IgM/IgG Antibody Fast Detection Kit for Distribution

ThermoGenesis Receives Acknowledgement Letter from FDA Allowing Its SARS-CoV-2 (COVID-19) IgM/IgG Antibody Fast Detection Kit for Distribution

RANCHO CORDOVA, Calif., April 16, 2020 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, announced today that on Wednesday April 15th, following submission of notification to the U.S. Food and Drug Administration (FDA), the Company has received the necessary acknowledgement letter which provided confirmation that the ThermoGenesis' SARS-CoV-2 (COVID-19) IgM/IgG Antibody Fast Detection Kit has been appropriately validated in accordance with Section IV.D. of the "Policy for Diagnostic Tests for Coronavirus Disease - 2019 during the Public Health Emergency," issued by FDA on March 16, 2020. The required registrations and listings with FDA have been completed, which now allow the diagnostic kit to be distributed.

An informational presentation on the COVID-19 Kit is available on the Company's website. The presentation is for educational purposes and will allow users to better understand how the antibody test works and how to evaluate the results. Please visit the link below:

Understanding the Rapid Covid-19 Point-of-Care Diagnostic Test - ThermoGenesis Corp.
As previously announced, the COVID-19 Kit will be jointly marketed by ThermoGenesis and ImmuneCyte Life Sciences, Inc. Inquiries from health professionals and the media about the Kit should be directed via email to ir@thermogenesis.com.

About ThermoGenesis Holdings, Inc.

ThermoGenesis Holdings, Inc. develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. The Company currently markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally-closed CAR-TXpress™ platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. For more information about ThermoGenesis, please visit: Home - ThermoGenesis Corp..

About ImmuneCyte Life Sciences, Inc.

ImmuneCyte develops and commercializes immunological products and services. The Company provides clients the opportunity to bank their own immune cells when the cells are "healthy and unaffected" as a future resource for cellular immunotherapies, such as CAR-T. ImmuneCyte utilizes a proprietary CAR-TXpress™ platform, a GMP compliant close-system capable of automated separating and cryopreserving different components from blood. For more information about ImmuneCyte Life Sciences Inc., please visit: Home - ImmuneCyte.

Speriamo Che tenga fino alle 15.30 così le mollo :bow:
 
Mollate in apertura OK!
 
+ 117% ora un pò di riposo

Bunny.jpg
 
sciort conclamato

frode

si fanno le JV in famiglia ... e schizzano in borsa ... vabbè ... se nn ci fossero gli stolti, chi gaina ? :asd:

On December 26, 2019, Boyalife (Hong Kong) Ltd. ("Boyalife HK") sold to Boyalife Asset Holding II, Inc. ("Boyalife AH") an aggregate of 683,824 shares of the Issuer's common stock for an aggregate purchase price of $2,227,134 (or $3.33 per share) and warrants to purchase 352,942 shares of issuer common stock for an aggregate purchase price of $10.00. Boyalife AH is 100% owned by Boyalife Group, Inc., which is 100% owned by Mr. Xiaochun Xu, and Boyalife HK is owned 100% by Ms. Yishu Li, the spouse of Mr. Xiaochun Xu. Accordingly, the transaction resulted in a change in the form of beneficial ownership of the shares and did not result in a change in Mr. Xu's and Ms. Li's pecuniary interest in the shares.
 
Ultima modifica:
About - ThermoGenesis Corp.

2016: Boyalife Group, a global diversified life science holding company, made a strategic investment in the Company and became the largest shareholder.

2019: Formed the joint venture ImmuneCyte with Healthbanks Biotech (USA) to provide immune cell banking, and cell-based contract manufacturing services utilizing the CAR-TXpress™ Platform.

ps HealthBanks Biotech is a subsidiary of Boyalife Group, Inc. (USA) :asd:

ThermoGenesis Holdings Closes Joint Venture Agreement With HealthBanks Biotech (USA) To Form ImmuneCyte Life Sciences - Bloomberg
 
purtroppo directa su questo titolo non da possibilità di short, se no ieri c'era da fare il grano
 
Indietro